Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.54 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880446 | 0.84 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2652269 | 0.81 | FFAR2 (0.57) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3794688 | 0.80 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2650712 | 0.79 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5653949 | 0.79 | CCNE1 (0.55) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2175131 | 0.78 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27867504 | 0.78 | SMN1; SMN2 (0.52) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6474925 | 0.77 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL26818237 | 0.77 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4394535 | 0.76 | FFAR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1640369-A1 | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | CMA1, TH, NPR3 | RAB9A 4477/4885NPC1 3145/4885SMN1; SMN2 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.